001, RAD,
40-O-(2-hydroxyethyl)-rapamycin,
Afinitor,
Certican,
everolimus,
RAD 001,
RAD, SDZ,
RAD001,
SDZ RAD,
SDZ-RAD,
Everolimus,
Afinitor,
Certican,
Zortress,
RAD001,
SDZ-RAD,
42-O-(2-Hydroxyethyl)rapamycin,
159351-69-6,
40-O-(2-hydroxyethyl)-rapamycin,
Afinitor Disperz,
CHEBI:68478,
Rapamycin, 42-O-(2-hydroxyethyl)-,
UNII-9HW64Q8G6G,
RAD 001,
9HW64Q8G6G,
RAD-001,
NCGC00167512-01,
(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,27-dihydroxy-3-{(2R)-1-[(1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl]propan-2-yl}-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-hexadecahydro-3H-23,27-epoxypyrido[2,1-c][1,4]oxazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone,
Votubia,
RAD,
XIENCE V,
(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.0(sup 4,9))hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone,
(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.04,9)hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone,
(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,35R)-1,18-dihydroxy-12-{(2R)-1-[(1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl]propan-2-yl}-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo[30.3.1.0(4,9)]hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentone,
(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-Hexadecahydro-9,27-dihydroxy-3-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-23,27-epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone,
Everolimus (RAD001),
everolimusum,
NSC733504,
Everolimus (INN),
Everolimus [USAN],
Everolimus(RAD001),
PubChem20048,
Everolimus - RAD001,
SCHEMBL4378,
DSSTox_CID_20599,
DSSTox_RID_79508,
DSSTox_GSID_40599,
Everolimus [USAN:INN:BAN],
NVP-RAD-001,
Everolimus, analytical standard,
GTPL5889,
RAD-001C,
CHEMBL1908360,
DTXSID0040599,
HSDB 8255,
Everolimus; RAD001; SDZ-RAD,
HKVAMNSJSFKALM-GKUWKFKPSA-N,
C53H83NO14,
EX-A2057,
Tox21_112510,
BDBM50088378,
AKOS015850977,
ZINC169677008,
CS-0064,
DB01590,
RL02051,
AS-16971,
AT-22180,
HY-10218,
LS-143292,
CAS-159351-69-6,
V2036,
351E696,
Q-101413,
BRD-K13514097-001-01-2,
BRD-K13514097-001-05-3,
dihydroxy-[(1R)-2-[(1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxy-cyclohexyl]-1-methyl-ethyl]-dimethoxy-hexamethyl-[?]pentone,
Everolimus solution, 1.0 mg/mL in acetonitrile, ampule of 1 mL, certified reference material,